Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

768.89 -18.61 (-2.36%)
Streaming Delayed Price Updated: 9:52 AM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
60 61 Next >
News headline image
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
News headline image
Stock Split Watch: 3 Growth Stocks That Could Be Next ↗
Success has some downsides, including a much higher stock price. 
Via The Motley Fool
News headline image
What's Going On With FibroGen Stock Tuesday? ↗
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
Via Benzinga
News headline image
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Biotech Stocks to Buy in May ↗
You could buy these in any month, really. 
Via The Motley Fool
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
FibroGen Stock Is Surging After The Bell: What's Going On? ↗
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector ↗
 
Via Benzinga
News headline image
What's Going On With Biohaven Stock Wednesday? ↗
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates. 
Via Benzinga
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years ↗
It might not be too late to invest in these impressive growth stocks. 
Via The Motley Fool
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
From Kirby McInerney LLP
Via Business Wire
News headline image
These 2 No-Brainer Growth Stocks Are Breaking New Ground ↗
The future keeps getting brighter for these companies. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Week Of May 13, 2024: What's In Store For The Markets ↗
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch. 
Via Talk Markets
News headline image
Healthcare And Biotech Investing 101: What You Need To Know. ↗
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sell In May? No Way! ↗
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away. 
Via Talk Markets
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.